Human Brachiocephalic Artery Endothelial Cells :HBcAEC-T2D (L).
Human Brachiocephalic Artery Endothelial Cells: Type 2 Diabetes: HBcAEC-T2D
Human Brachiocephalic Artery Endothelial Cells from donors with Type 2 Diabetes (HBcAEC-T2D) are primary endothelial cells isolated from the normal human brachiocephalic artery from donors with Type 2 Diabetes.
Description
Human Brachiocephalic Artery Endothelial Cells from donors with Type 2 Diabetes (HBcAEC-T2D) are a physiologically relevant human vascular endothelial cell model for studying how diabetes reshapes blood vessel biology at the level of the endothelium. As with human endothelial cells from other vascular beds, these endothelial cells maintain a specialized interface between circulating blood and the vessel wall, regulating vascular tone, thrombosis, permeability, and leukocyte recruitment. Because endothelial phenotype is strongly influenced by local biomechanical cues — such as blood flow and shear stress — and by the molecular composition of the arterial environment, endothelial function differs across vascular territories even within the same individual. In this context, coronary artery endothelial cells and brachiocephalic artery endothelial cells can display distinct baseline properties and distinct inflammatory responses, reflecting vascular heterogeneity across blood vessels and the endothelium of specific beds.
In diabetes, exposure to dysregulated glucose levels and chronic metabolic stress contributes to a shift from endothelial homeostasis toward endothelial dysfunction. In HBcAEC-T2D, diabetes mellitus and related metabolic syndrome features — including hyperglycemia, elevated circulating glucose, and a pro-atherogenic milieu — are expected to promote vascular inflammation and vascular dysfunction through multiple converging pathways. Among the earliest and best-characterized consequences is impaired regulation of vascular tone due to reduced availability of endothelial nitric oxide synthase activity and/or signaling. Endothelial nitric oxide synthase is central for maintaining vascular function by supporting nitric oxide–mediated vasodilation and anti-inflammatory signaling; when its function is compromised, vascular endothelial cells become less able to counteract vasoconstrictor stimuli and oxidative stress. This molecular shift can connect diabetes to cardiovascular risk and vascular complications that ultimately manifest as cardiovascular diseases, atherosclerosis, and other vascular disease phenotypes observed in diabetic patients and T2DM patients.
Beyond nitric oxide pathways, diabetes-associated changes can alter the expression and post-translational state of surface molecules that coordinate leukocyte adhesion and transmigration. Importantly, endothelial inflammation in different arterial beds can be shaped by differential N-glycosylation of commonly expressed vascular adhesion molecules. Such glycosylation differences can modify receptor binding, clustering, and downstream signaling under resting versus activated conditions, thereby influencing leukocyte recruitment and propagating inflammation. This mechanism provides a coherent explanation for why specific vascular beds may be more or less susceptible to particular diabetic complication trajectories, including vascular inflammation that contributes to diabetic complication and peripheral artery disease. When endothelial cells from a given individual are used, donor-to-donor confounders — such as genetic variability and lifestyle factors — are reduced, enabling more interpretable comparisons that reflect the diabetes state rather than uncontrolled heterogeneity.
Consistent with these principles, HBcAEC-T2D offer a targeted system to examine how type 2 diabetes reshapes vascular function in the arteries most directly relevant to systemic blood flow and cardiovascular risk factor pathways. At the cellular level, glucose and diabetes-driven metabolic stress are expected to influence endothelium–immune interactions, oxidative balance, and vascular endothelial cell signaling, producing glucose- and hyperglycemia-associated vascular dysfunction alongside altered vascular inflammation. These changes can increase susceptibility to cardiovascular diseases by promoting atherosclerosis-like inflammation, endothelial activation, and vascular disease progression. In turn, the biology captured by this model is closely aligned with clinical realities in which high glucose, insulin resistance, and long-term metabolic exposure elevate cardiovascular risk and contribute to vascular complications, including effects on blood pressue and disease progression within the arterial circulation.
Finally, studying HBcAEC-T2D alongside other human arterial endothelial sources such as coronary artery endothelial cells can clarify how diabetes intersects with intrinsic vascular heterogeneity. Because vascular disease risk and diabetic complication burden vary by vessel type and hemodynamic context, careful comparison of endothelial dysfunction versus preserved endothelial function across vascular beds can help identify mechanisms that distinguish diabetes-driven cardiovascular diseases. Such insights are valuable for understanding how vascular inflammation, vascular endothelial dysfunction, and disturbed signaling converge to produce cardiovascular disease outcomes in diabetic patients, T2DM patients, and individuals with diabetes mellitus and its associated cardiovascular risk factor profiles.
Human Brachiocephalic Artery Endothelial Cells (HBcAEC) along with human aortic (HAOEC), carotid artery (HCtAEC), coronary artery (HCAEC) and subclavian artery (HScAEC), all from Cell Applications, Inc., have been used to demonstrate that not only blood vessels from different tissues are highly heterogeneous, they also interact differently with leukocytes during the inflammation response. The authors further showed that differential N-glycosylation of commonly expressed vascular adhesion molecules may be responsible for this heterogeneity, as well as for modulation of signaling under resting and activated inflammatory conditions. This also explains why specific vascular beds may be more or less susceptible to particular diseases or stimuli. Importantly, if cells from different sources were used, these results could not be convincingly validated due to a number of uncontrolled variables, such as age, race, genetic variability or life style choices of the donors. To eliminate the donor-to-donor variability, the scientists took advantage of the great variety of primary cells offered by Cell Applications, including the option of ordering a panel of endothelial cells obtained from different vascular beds of the same donor!
Because of the complex heterogeneity that exists not only between different donors, but even between different vascular beds in the same individual, it would be prudent to confirm any new findings on primary cell lots coming from several different origins.
Type 2 Diabetes (T2D) Cellular Disease Models For T2D research and drug discovery, Cell Applications offers multiple cell types, isolated from donors where genetics and lifestyle factors contributed to insulin resistance and high blood sugar levels.
Details
| Tissue | Human brachiocephalic artery from donor with Type 2 Diabetes (T2D) | |
|---|---|---|
| QC | No bacteria, yeast, fungi, mycoplasma, virus | |
| Character | Factor VIII-related Ag, DiI-Ac-LDL uptake | |
| Bioassay | Attach, spread, proliferate in Growth Med | |
| Cryovial | 500,000 HBcAEC-T2D (2nd psg) frozen in Basal Medium w/10% FBS, 10% DMSO | |
| Kit | Cryovial frozen HBcAEC-T2D (3012T2D-05a), Growth Medium (212-500), Subculture Rgnt Kit (090K) | |
| Proliferating | Shipped in Tsfr Med, 3rd psg (flasks or plates) | |
| Doublings | At least 12 | |
| Applications | Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use. |
Resources
FAQs
Need More Help?
Visit our comprehensive FAQ page for detailed answers to common questions.
Need More Help?
Visit our comprehensive FAQ page for detailed answers to common questions.
Primary Cell FAQs